Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
New technology has transformed human genetics. It now provides perhaps the single best opportunity to innovate and improve clinical success rates in drug development.
Too few precompetitive consortia are being formed to mitigate lost opportunities and deliver on other potential mutual gains for public and private stakeholders in drug development.
Open collaboration on biomedical discoveries requires a fundamental shift in the traditional roles and rewards for both investigators and participants in research.